Effects of intravitreal aflibercept and ranibizumab on retinal vessel diameter measured using fluorescein angiography

Acta Ophthalmol. 2018 Jun;96(4):e546-e547. doi: 10.1111/aos.13561. Epub 2017 Oct 25.

Authors

Jung Kee Min¹, Seunghwan Lee¹, Jong Hoon Park², Je Moon Woo¹, Hyun Seung Yang¹

Affiliations

¹ Department of Ophthalmology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
² Department of Ophthalmology, Seoul Shinsegae Eye Centre, Eui Jung Bu, Gyeonggi-do, Korea.

PMID: 29068524
DOI: 10.1111/aos.13561

No abstract available

Publication types

Letter

MeSH terms

Aged
Angiogenesis Inhibitors / therapeutic use*
Constriction, Pathologic
Female
Fluorescein Angiography
Humans
Intravitreal Injections
Male
Middle Aged
Ranibizumab / therapeutic use*
Receptors, Vascular Endothelial Growth Factor / therapeutic use*
Recombinant Fusion Proteins / therapeutic use*
Retinal Vessels / drug effects*
Retinal Vessels / pathology
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Wet Macular Degeneration / diagnosis
Wet Macular Degeneration / drug therapy*

Substances

Angiogenesis Inhibitors
Recombinant Fusion Proteins
VEGFA protein, human
Vascular Endothelial Growth Factor A
aflibercept
Receptors, Vascular Endothelial Growth Factor
Ranibizumab